Importance Chronic lymphocytic leukemia (CLL), defined by a minimum of 5× 10 9/L
monoclonal B cells in the blood, affects more than 200 000 people and is associated with …

Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in
the past two decades have led to the development of new prognostic tools and novel …

Background Both single-agent ibrutinib and chlorambucil plus obinutuzumab have shown
superior efficacy to chlorambucil monotherapy and are standard first-line treatments in …

Background Chronic lymphocytic leukemia (CLL) primarily affects older persons who often
have coexisting conditions in addition to disease-related immunosuppression and …

Therapeutic monoclonal antibodies are the fastest growing class of biological therapeutics
for the treatment of various cancers and inflammatory disorders. In cancer immunotherapy …

Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the Western world
with an incidence of 4.2/100 000/year. The incidence increases to more than 30/100 …

Aberrant glycosylation is a universal feature of cancer cells that can impact all steps in
tumour progression from malignant transformation to metastasis and immune evasion. One …

The field of chronic lymphocytic leukemia (CLL) has witnessed considerable change since
the time clinical staging was introduced in clinical practice in 1975. Over the years, the …

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are
characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone …

While rituximab has dramatically improved outcomes for patients with CD20+ malignancies
for two decades, responses are not universal and resistance can develop. Obinutuzumab …